Amedisys Statistics
Total Valuation
Amedisys has a market cap or net worth of $2.95 billion. The enterprise value is $3.22 billion.
| Market Cap | 2.95B |
| Enterprise Value | 3.22B |
Important Dates
The last earnings date was Wednesday, November 6, 2024, after market close.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Amedisys has 32.75 million shares outstanding. The number of shares has increased by 1.05% in one year.
| Current Share Class | 32.75M |
| Shares Outstanding | 32.75M |
| Shares Change (YoY) | +1.05% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 1.99% |
| Owned by Institutions (%) | 90.38% |
| Float | 32.08M |
Valuation Ratios
The trailing PE ratio is 35.72 and the forward PE ratio is 18.82. Amedisys's PEG ratio is 3.18.
| PE Ratio | 35.72 |
| Forward PE | 18.82 |
| PS Ratio | 1.27 |
| Forward PS | 1.19 |
| PB Ratio | 2.57 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.42 |
| P/OCF Ratio | 13.92 |
| PEG Ratio | 3.18 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.76, with an EV/FCF ratio of 15.77.
| EV / Earnings | 38.86 |
| EV / Sales | 1.39 |
| EV / EBITDA | 13.76 |
| EV / EBIT | 15.42 |
| EV / FCF | 15.77 |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 0.39.
| Current Ratio | 1.19 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | 1.77 |
| Debt / FCF | 2.29 |
| Interest Coverage | 6.52 |
Financial Efficiency
Return on equity (ROE) is 7.21% and return on invested capital (ROIC) is 8.03%.
| Return on Equity (ROE) | 7.21% |
| Return on Assets (ROA) | 6.27% |
| Return on Capital (ROIC) | 8.03% |
| Revenue Per Employee | $122,161 |
| Profits Per Employee | $4,365 |
| Employee Count | 19,000 |
| Asset Turnover | 1.11 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Amedisys has paid $51.94 million in taxes.
| Income Tax | 51.94M |
| Effective Tax Rate | 38.58% |
Stock Price Statistics
The stock price has decreased by -3.72% in the last 52 weeks. The beta is 0.78, so Amedisys's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -3.72% |
| 50-Day Moving Average | 95.73 |
| 200-Day Moving Average | 94.84 |
| Relative Strength Index (RSI) | 27.47 |
| Average Volume (20 Days) | 662,368 |
Short Selling Information
The latest short interest is 2.26 million, so 6.91% of the outstanding shares have been sold short.
| Short Interest | 2.26M |
| Short Previous Month | 1.64M |
| Short % of Shares Out | 6.91% |
| Short % of Float | 7.05% |
| Short Ratio (days to cover) | 5.97 |
Income Statement
In the last 12 months, Amedisys had revenue of $2.32 billion and earned $82.93 million in profits. Earnings per share was $2.52.
| Revenue | 2.32B |
| Gross Profit | 1.01B |
| Operating Income | 208.93M |
| Pretax Income | 143.78M |
| Net Income | 82.93M |
| EBITDA | 234.15M |
| EBIT | 208.93M |
| Earnings Per Share (EPS) | $2.52 |
Balance Sheet
The company has $245.45 million in cash and $467.67 million in debt, giving a net cash position of -$222.22 million or -$6.79 per share.
| Cash & Cash Equivalents | 245.45M |
| Total Debt | 467.67M |
| Net Cash | -222.22M |
| Net Cash Per Share | -$6.79 |
| Equity (Book Value) | 1.20B |
| Book Value Per Share | 35.05 |
| Working Capital | 93.93M |
Cash Flow
In the last 12 months, operating cash flow was $211.70 million and capital expenditures -$7.33 million, giving a free cash flow of $204.37 million.
| Operating Cash Flow | 211.70M |
| Capital Expenditures | -7.33M |
| Free Cash Flow | 204.37M |
| FCF Per Share | $6.24 |
Margins
Gross margin is 43.67%, with operating and profit margins of 9.00% and 3.57%.
| Gross Margin | 43.67% |
| Operating Margin | 9.00% |
| Pretax Margin | 5.80% |
| Profit Margin | 3.57% |
| EBITDA Margin | 10.09% |
| EBIT Margin | 9.00% |
| FCF Margin | 3.90% |
Dividends & Yields
Amedisys does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.05% |
| Shareholder Yield | -1.05% |
| Earnings Yield | 2.81% |
| FCF Yield | 6.93% |
Analyst Forecast
The average price target for Amedisys is $100.67, which is 11.84% higher than the current price. The consensus rating is "Hold".
| Price Target | $100.67 |
| Price Target Difference | 11.84% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 5, 2006. It was a forward split with a ratio of 1.33333:1.
| Last Split Date | Dec 5, 2006 |
| Split Type | Forward |
| Split Ratio | 1.33333:1 |
Scores
Amedisys has an Altman Z-Score of 3.96 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.96 |
| Piotroski F-Score | 7 |